☰
×
News
Top 20
Insights
Insights+
ThoughtSpot
Interviews
Viewpoints
Exclusive
Spotlight
Events
Magazine
Bespoke
Newswire
x
Search
Search here
Search here
Subscribe Now
Zealand Pharma
Zealand Pharma and Boehringer Ingelheim Report the US FDA’s Breakthrough Therapy Designation of Survodutide for MASH
October 8, 2024
Zealand Pharma Submits an NDA for Glepaglutide to the US FDA for the Treatment of Short Bowel Syndrome (SBS)
December 26, 2023
Zealand Pharma Reports Part 1 Results of Multiple Ascending Dose Trial for ZP8396 for the Management of Overweight and Obesity
July 3, 2023
Zealand Pharma Reports Results from P-Ia Study of ZP8396 for Patients with Obesity and Diabetes
March 28, 2023
Zealand Pharma Reports P-III (EASE 1) Trial Results of Glepaglutide for the Treatment of Short Bowel Syndrome
September 30, 2022
Zealand Pharma Report Enrollment Completion in P-III Study of Dasiglucagon in Children with Congenital Hyperinsulinism
February 15, 2022
Load more...
Back to Home
Modal title
×
Modal body text goes here.